Suchergebnisse - "de Miguel-Luken, María José"

PubPharm (10)

1

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC) : Data from the Phase 1 NSCLC expansion cohort

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Moreno, V. | Garrido, P. | Papadopoulos, K. | +10

2

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates : a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Hurtado, F. | de Braud, F. | De Castro Carpeño, J. | +6

3

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Hurtado, F. | de Braud, F. | De Castro Carpeño, J. | +6

4

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Hurtado, F. | de Braud, F. | De Castro Carpeño, J. | +6

5

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Hurtado, F. | de Braud, F. | De Castro Carpeño, J. | +6

6

Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations

enthalten in: JCO precision oncology | 2019

von Hyman, D. | Tran, B. | Paz-Ares, L. | +21

7

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit

enthalten in: European journal of cancer (Oxford, England : 1990) | 2017

von Papadatos-Pastos, D. | Roda, D. | De Miguel Luken, M. | +13

8

Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival

enthalten in: Oncotarget | 2016

von de Miguel-Luken, M. | Chaves-Conde, M. | Quintana, B. | +7

9

A genetic view of laryngeal cancer heterogeneity

enthalten in: Cell cycle (Georgetown, Tex.) | 2016

von de Miguel-Luken, M. | Chaves-Conde, M. | Carnero, A.

10

MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer

enthalten in: Oncotarget | 2015

von de Miguel-Luken, M. | Chaves-Conde, M. | de Miguel-Luken, V. | +7

1
[1]